Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups. This study was performed to evaluate the use of high-dose nafamostat mesilate (50 mg) for prevention of post-ERCP pancreatitis (PEP), especially in high-risk group...
Gespeichert in:
| Veröffentlicht in: | Pancreas 2011-11, Vol.40 (8), p.1215-1219 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1219 |
|---|---|
| container_issue | 8 |
| container_start_page | 1215 |
| container_title | Pancreas |
| container_volume | 40 |
| creator | Park, Kee Tae Kang, Dae Hwan Choi, Cheol Woong Cho, Mong Park, Su Bum Kim, Hyung Wook Kim, Dong Uk Chung, Chung Wook Yoon, Ki Tae |
| description | Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups. This study was performed to evaluate the use of high-dose nafamostat mesilate (50 mg) for prevention of post-ERCP pancreatitis (PEP), especially in high-risk groups.
A total of 608 patients who underwent ERCP were included; 13 patients were excluded. Patients were divided into 3 groups: controls (group A), infusion with 20 mg of nafamostat mesilate (group B), or infusion with 50 mg of nafamostat mesilate (group C). The incidence of PEP was analyzed.
The overall incidence of acute pancreatitis was 7.4% (44/595). There was a significant difference in the incidence of PEP with or without nafamostat mesilate (13.0% vs 4.0% and 5.1%, respectively; P < 0.0001). Subgroup analysis showed that in low-risk patients, the rate of PEP was significantly different with nafamostat (11.9% vs 2.7% and 4.0%, respectively; P = 0.007). In high-risk patients, the rate of PEP was not significantly different among treatment groups (14.6% vs 5.9% vs 6.9%, respectively; P = 0.108).
Nafamostat mesilate prophylaxis (20 or 50 mg) is effective in preventing post-ERCP pancreatitis. However, the preventive effect of high-dose nafamostat mesilate (50 mg) is not significant in high-risk patients. |
| doi_str_mv | 10.1097/MPA.0b013e31822116d5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_898840825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>898840825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-adf17e576b32be71d67e4dabdec3466ccb6671adea4dfe1e5855db23bc5c59843</originalsourceid><addsrcrecordid>eNpdkEtLAzEUhYMotlb_gUh2bpyaTCaTzEpK8VFQLKLrIZPc2Oi8TFKh_npHWl24unD5zjnwIXRKyZSSQlw-LGdTUhHKgFGZppTmhu-hMeUsTzKZyn00JlLyhFEhRugohDdCqGC8OESjdPjxgsox-loEvHKvq8R0AXCrrGq6EFXEDQRXqwgYrAUd3Sdg23kcV4B7D5_QRte1uLO4H_jk-mm-xL1qtQcVXXThAkPoQTtV1xvs2u2Gd-F9oKIb0uHqGB1YVQc42d0Jerm5fp7fJfePt4v57D7RTKQxUcZSAVzkFUsrENTkAjKjKgOaZXmudZXngioDKjMWKHDJualSVmmueSEzNkHn297edx9rCLFsXNBQ16qFbh1KWUiZEZnygcy2pPZdCB5s2XvXKL8pKSl_pJeD9PK_9CF2thtYVw2Yv9CvZfYN1O6BEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>898840825</pqid></control><display><type>article</type><title>Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Park, Kee Tae ; Kang, Dae Hwan ; Choi, Cheol Woong ; Cho, Mong ; Park, Su Bum ; Kim, Hyung Wook ; Kim, Dong Uk ; Chung, Chung Wook ; Yoon, Ki Tae</creator><creatorcontrib>Park, Kee Tae ; Kang, Dae Hwan ; Choi, Cheol Woong ; Cho, Mong ; Park, Su Bum ; Kim, Hyung Wook ; Kim, Dong Uk ; Chung, Chung Wook ; Yoon, Ki Tae</creatorcontrib><description>Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups. This study was performed to evaluate the use of high-dose nafamostat mesilate (50 mg) for prevention of post-ERCP pancreatitis (PEP), especially in high-risk groups.
A total of 608 patients who underwent ERCP were included; 13 patients were excluded. Patients were divided into 3 groups: controls (group A), infusion with 20 mg of nafamostat mesilate (group B), or infusion with 50 mg of nafamostat mesilate (group C). The incidence of PEP was analyzed.
The overall incidence of acute pancreatitis was 7.4% (44/595). There was a significant difference in the incidence of PEP with or without nafamostat mesilate (13.0% vs 4.0% and 5.1%, respectively; P < 0.0001). Subgroup analysis showed that in low-risk patients, the rate of PEP was significantly different with nafamostat (11.9% vs 2.7% and 4.0%, respectively; P = 0.007). In high-risk patients, the rate of PEP was not significantly different among treatment groups (14.6% vs 5.9% vs 6.9%, respectively; P = 0.108).
Nafamostat mesilate prophylaxis (20 or 50 mg) is effective in preventing post-ERCP pancreatitis. However, the preventive effect of high-dose nafamostat mesilate (50 mg) is not significant in high-risk patients.</description><identifier>ISSN: 0885-3177</identifier><identifier>EISSN: 1536-4828</identifier><identifier>DOI: 10.1097/MPA.0b013e31822116d5</identifier><identifier>PMID: 21775918</identifier><language>eng</language><publisher>United States</publisher><subject>Acute Disease ; Aged ; Amylases - blood ; Cholangiopancreatography, Endoscopic Retrograde - adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Guanidines - administration & dosage ; Guanidines - therapeutic use ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Pancreatitis - blood ; Pancreatitis - etiology ; Pancreatitis - prevention & control ; Prospective Studies ; Protease Inhibitors - administration & dosage ; Protease Inhibitors - therapeutic use ; Risk Factors ; Time Factors ; Treatment Outcome</subject><ispartof>Pancreas, 2011-11, Vol.40 (8), p.1215-1219</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-adf17e576b32be71d67e4dabdec3466ccb6671adea4dfe1e5855db23bc5c59843</citedby><cites>FETCH-LOGICAL-c372t-adf17e576b32be71d67e4dabdec3466ccb6671adea4dfe1e5855db23bc5c59843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21775918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Kee Tae</creatorcontrib><creatorcontrib>Kang, Dae Hwan</creatorcontrib><creatorcontrib>Choi, Cheol Woong</creatorcontrib><creatorcontrib>Cho, Mong</creatorcontrib><creatorcontrib>Park, Su Bum</creatorcontrib><creatorcontrib>Kim, Hyung Wook</creatorcontrib><creatorcontrib>Kim, Dong Uk</creatorcontrib><creatorcontrib>Chung, Chung Wook</creatorcontrib><creatorcontrib>Yoon, Ki Tae</creatorcontrib><title>Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?</title><title>Pancreas</title><addtitle>Pancreas</addtitle><description>Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups. This study was performed to evaluate the use of high-dose nafamostat mesilate (50 mg) for prevention of post-ERCP pancreatitis (PEP), especially in high-risk groups.
A total of 608 patients who underwent ERCP were included; 13 patients were excluded. Patients were divided into 3 groups: controls (group A), infusion with 20 mg of nafamostat mesilate (group B), or infusion with 50 mg of nafamostat mesilate (group C). The incidence of PEP was analyzed.
The overall incidence of acute pancreatitis was 7.4% (44/595). There was a significant difference in the incidence of PEP with or without nafamostat mesilate (13.0% vs 4.0% and 5.1%, respectively; P < 0.0001). Subgroup analysis showed that in low-risk patients, the rate of PEP was significantly different with nafamostat (11.9% vs 2.7% and 4.0%, respectively; P = 0.007). In high-risk patients, the rate of PEP was not significantly different among treatment groups (14.6% vs 5.9% vs 6.9%, respectively; P = 0.108).
Nafamostat mesilate prophylaxis (20 or 50 mg) is effective in preventing post-ERCP pancreatitis. However, the preventive effect of high-dose nafamostat mesilate (50 mg) is not significant in high-risk patients.</description><subject>Acute Disease</subject><subject>Aged</subject><subject>Amylases - blood</subject><subject>Cholangiopancreatography, Endoscopic Retrograde - adverse effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Guanidines - administration & dosage</subject><subject>Guanidines - therapeutic use</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pancreatitis - blood</subject><subject>Pancreatitis - etiology</subject><subject>Pancreatitis - prevention & control</subject><subject>Prospective Studies</subject><subject>Protease Inhibitors - administration & dosage</subject><subject>Protease Inhibitors - therapeutic use</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0885-3177</issn><issn>1536-4828</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEtLAzEUhYMotlb_gUh2bpyaTCaTzEpK8VFQLKLrIZPc2Oi8TFKh_npHWl24unD5zjnwIXRKyZSSQlw-LGdTUhHKgFGZppTmhu-hMeUsTzKZyn00JlLyhFEhRugohDdCqGC8OESjdPjxgsox-loEvHKvq8R0AXCrrGq6EFXEDQRXqwgYrAUd3Sdg23kcV4B7D5_QRte1uLO4H_jk-mm-xL1qtQcVXXThAkPoQTtV1xvs2u2Gd-F9oKIb0uHqGB1YVQc42d0Jerm5fp7fJfePt4v57D7RTKQxUcZSAVzkFUsrENTkAjKjKgOaZXmudZXngioDKjMWKHDJualSVmmueSEzNkHn297edx9rCLFsXNBQ16qFbh1KWUiZEZnygcy2pPZdCB5s2XvXKL8pKSl_pJeD9PK_9CF2thtYVw2Yv9CvZfYN1O6BEg</recordid><startdate>201111</startdate><enddate>201111</enddate><creator>Park, Kee Tae</creator><creator>Kang, Dae Hwan</creator><creator>Choi, Cheol Woong</creator><creator>Cho, Mong</creator><creator>Park, Su Bum</creator><creator>Kim, Hyung Wook</creator><creator>Kim, Dong Uk</creator><creator>Chung, Chung Wook</creator><creator>Yoon, Ki Tae</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201111</creationdate><title>Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?</title><author>Park, Kee Tae ; Kang, Dae Hwan ; Choi, Cheol Woong ; Cho, Mong ; Park, Su Bum ; Kim, Hyung Wook ; Kim, Dong Uk ; Chung, Chung Wook ; Yoon, Ki Tae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-adf17e576b32be71d67e4dabdec3466ccb6671adea4dfe1e5855db23bc5c59843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acute Disease</topic><topic>Aged</topic><topic>Amylases - blood</topic><topic>Cholangiopancreatography, Endoscopic Retrograde - adverse effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Guanidines - administration & dosage</topic><topic>Guanidines - therapeutic use</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pancreatitis - blood</topic><topic>Pancreatitis - etiology</topic><topic>Pancreatitis - prevention & control</topic><topic>Prospective Studies</topic><topic>Protease Inhibitors - administration & dosage</topic><topic>Protease Inhibitors - therapeutic use</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Kee Tae</creatorcontrib><creatorcontrib>Kang, Dae Hwan</creatorcontrib><creatorcontrib>Choi, Cheol Woong</creatorcontrib><creatorcontrib>Cho, Mong</creatorcontrib><creatorcontrib>Park, Su Bum</creatorcontrib><creatorcontrib>Kim, Hyung Wook</creatorcontrib><creatorcontrib>Kim, Dong Uk</creatorcontrib><creatorcontrib>Chung, Chung Wook</creatorcontrib><creatorcontrib>Yoon, Ki Tae</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pancreas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Kee Tae</au><au>Kang, Dae Hwan</au><au>Choi, Cheol Woong</au><au>Cho, Mong</au><au>Park, Su Bum</au><au>Kim, Hyung Wook</au><au>Kim, Dong Uk</au><au>Chung, Chung Wook</au><au>Yoon, Ki Tae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?</atitle><jtitle>Pancreas</jtitle><addtitle>Pancreas</addtitle><date>2011-11</date><risdate>2011</risdate><volume>40</volume><issue>8</issue><spage>1215</spage><epage>1219</epage><pages>1215-1219</pages><issn>0885-3177</issn><eissn>1536-4828</eissn><abstract>Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups. This study was performed to evaluate the use of high-dose nafamostat mesilate (50 mg) for prevention of post-ERCP pancreatitis (PEP), especially in high-risk groups.
A total of 608 patients who underwent ERCP were included; 13 patients were excluded. Patients were divided into 3 groups: controls (group A), infusion with 20 mg of nafamostat mesilate (group B), or infusion with 50 mg of nafamostat mesilate (group C). The incidence of PEP was analyzed.
The overall incidence of acute pancreatitis was 7.4% (44/595). There was a significant difference in the incidence of PEP with or without nafamostat mesilate (13.0% vs 4.0% and 5.1%, respectively; P < 0.0001). Subgroup analysis showed that in low-risk patients, the rate of PEP was significantly different with nafamostat (11.9% vs 2.7% and 4.0%, respectively; P = 0.007). In high-risk patients, the rate of PEP was not significantly different among treatment groups (14.6% vs 5.9% vs 6.9%, respectively; P = 0.108).
Nafamostat mesilate prophylaxis (20 or 50 mg) is effective in preventing post-ERCP pancreatitis. However, the preventive effect of high-dose nafamostat mesilate (50 mg) is not significant in high-risk patients.</abstract><cop>United States</cop><pmid>21775918</pmid><doi>10.1097/MPA.0b013e31822116d5</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3177 |
| ispartof | Pancreas, 2011-11, Vol.40 (8), p.1215-1219 |
| issn | 0885-3177 1536-4828 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_898840825 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Acute Disease Aged Amylases - blood Cholangiopancreatography, Endoscopic Retrograde - adverse effects Dose-Response Relationship, Drug Drug Administration Schedule Female Guanidines - administration & dosage Guanidines - therapeutic use Humans Infusions, Intravenous Male Middle Aged Pancreatitis - blood Pancreatitis - etiology Pancreatitis - prevention & control Prospective Studies Protease Inhibitors - administration & dosage Protease Inhibitors - therapeutic use Risk Factors Time Factors Treatment Outcome |
| title | Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T19%3A12%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20high-dose%20nafamostat%20mesilate%20effective%20for%20the%20prevention%20of%20post-ERCP%20pancreatitis,%20especially%20in%20high-risk%20patients?&rft.jtitle=Pancreas&rft.au=Park,%20Kee%20Tae&rft.date=2011-11&rft.volume=40&rft.issue=8&rft.spage=1215&rft.epage=1219&rft.pages=1215-1219&rft.issn=0885-3177&rft.eissn=1536-4828&rft_id=info:doi/10.1097/MPA.0b013e31822116d5&rft_dat=%3Cproquest_cross%3E898840825%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=898840825&rft_id=info:pmid/21775918&rfr_iscdi=true |